Guangzhou Institutes of Biomedicine and Health has disclosed bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of diabetes, autoimmune diseases, cardiovascular disorders, male contraception, chronic obstructive pulmonary disease, viral and parasitic infections and cancer.